We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Paul Seligman has been appointed the Associate Center Director for Safety Policy and Communication in the Center for Drug Evaluation and Research (CDER), FDA says.
Andrew von Eschenbach, President Bush’s pick to be the permanent commissioner of the FDA, has addressed a longstanding concerns critics have had about his appointment by resigning as director of the National Cancer Institute (NCI).
A recent study finds that multiple sclerosis (MS) patients may prefer to choose their own drug therapy when given the option, even if that choice involves an increased risk for dangerous or possibly fatal side effects.
AdvaMed released a proposal earlier this month on pulse generator product performance reports, designed to improve communication between the manufacturers of cardiac rhythm management devices and patients, insurance providers and the public.
The FDA has appointed a former high-ranking official at the Biotechnology Industry Organization (BIO) who has specialized in biodefense to be the agency’s liaison to Congress and develop the FDA’s legislative proposals.
Senate Democrats are threatening to hold up the nomination of Andrew von Eschenbach to be the permanent head of the FDA because of delays in the agency’s decision on whether to allow the controversial Plan B contraceptive to be sold without a prescription.
Senate Democrats are threatening to hold up the nomination of Andrew von Eschenbach to be the permanent head of the FDA over delays in the agency’s decision on whether to allow the controversial Plan B contraceptive to be sold without a prescription.
The FDA has appointed a former high-ranking official at the Biotechnology Industry Organization (BIO) to be the agency's liaison to Congress and develop the FDA's legislative proposals.
Andrew von Eschenbach's dual role as acting FDA commissioner and head of the National Cancer Institute (NCI) is a key factor in arguments both for and against his likely nomination to become the permanent FDA commissioner, sources say.